Literature DB >> 19349956

Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.

S Vokurka1, K Steinerova, M Karas, V Koza.   

Abstract

The fludarabine (FLU)/melphalan (MEL) conditioning regimen containing FLU and high-dose MEL was analyzed in comparison with the BU/CY2 regimen to characterize oral mucositis (OM) and risk factors. OM incidence significantly varied between BU/CY2 and FLU/MEL (100 vs 78%, P=0.004), but the incidence of severe OM grades 3-4 WHO and kinetics of OM were fully comparable. Patients with OM persisting on day +21 had more acute GVHD (68 vs 32%, P=0.005), which tended to occur earlier than among those without such prolonged OM. Multivariate analysis showed significant dependency of acute GVHD on severity and prolonged duration of OM and significant correlation between OM severity and its prolonged duration. Body surface area-based dosing in the FLU/MEL regimen led to a wide range of MEL doses administered per kilogram body weight (2.5-5.2 mg/kg, median 3.5). In multivariate analysis, MEL dose per kilogram of body weight was found to be a significant predictor of OM incidence and severity. Female gender and lower body mass index were less important variables than the fact that the actual dose of MEL administered per kilogram of body weight was relatively high when the dosage was calculated on the basis of body surface area.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349956     DOI: 10.1038/bmt.2009.66

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  A comparison of oral mucositis in allogeneic hematopoietic stem cell transplantation between conventional and reduced-intensity regimens.

Authors:  Haruhiko Kashiwazaki; Takae Matsushita; Junichi Sugita; Akio Shigematsu; Kumiko Kasashi; Yutaka Yamazaki; Takashi Kanehira; Takeshi Kondo; Tomoyuki Endo; Junji Tanaka; Satoshi Hashino; Mitsufumi Nishio; Masahiro Imamura; Yoshimasa Kitagawa; Nobuo Inoue
Journal:  Support Care Cancer       Date:  2011-04-15       Impact factor: 3.603

2.  Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.

Authors:  Tomoaki Ueda; Tomoyasu Jo; Kazuya Okada; Yasuyuki Arai; Takayuki Sato; Takeshi Maeda; Tatsuhito Onishi; Yasunori Ueda
Journal:  Int J Hematol       Date:  2019-11-07       Impact factor: 2.490

3.  Platelet lysate mucohadesive formulation to treat oral mucositis in graft versus host disease patients: a new therapeutic approach.

Authors:  Claudia Del Fante; Cesare Perotti; Maria Cristina Bonferoni; Silvia Rossi; Giuseppina Sandri; Franca Ferrari; Luigia Scudeller; Carla Marcella Caramella
Journal:  AAPS PharmSciTech       Date:  2011-07-06       Impact factor: 3.246

4.  Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.

Authors:  Tomoaki Ueda; Tetsuo Maeda; Shinsuke Kusakabe; Jiro Fujita; Kentaro Fukushima; Takafumi Yokota; Hirohiko Shibayama; Yoshiaki Tomiyama; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2018-11-17       Impact factor: 2.490

Review 5.  Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis.

Authors:  S Ben-Barouch; O Cohen; L Vidal; I Avivi; R Ram
Journal:  Bone Marrow Transplant       Date:  2015-10-12       Impact factor: 5.483

6.  Intensive oral care can reduce bloodstream infection with coagulase-negative staphylococci after neutrophil engraftment in allogeneic hematopoietic stem-cell transplantation.

Authors:  Tatsuya Suwabe; Kyoko Fuse; Kouji Katsura; Marie Soga; Takayuki Katagiri; Yasuhiko Shibasaki; Miwako Narita; Hirohito Sone; Masayoshi Masuko
Journal:  Support Care Cancer       Date:  2021-07-27       Impact factor: 3.603

7.  Incidence and Risk Factors of Oral Mucositis in Patients with Breast Cancer Who Receiving Chemotherapy in Al-Bashir Hospital.

Authors:  Ahmed A Al Ibraheemi; Shaimaa Shamoun
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-10-01

8.  Factors Affecting the Incidence and Severity of Oral Mucositis Following Hematopoietic Stem Cell Transplantation.

Authors:  Maryam Valeh; Mona Kargar; Ava Mansouri; Hosein Kamranzadeh; Kheirollah Gholami; Kazem Heidari; Moluk Hajibabaei
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-04-01

Review 9.  Oral complications in hematopoietic stem cell recipients: the role of inflammation.

Authors:  T M Haverman; J E Raber-Durlacher; W M H Rademacher; S Vokurka; J B Epstein; C Huisman; M D Hazenberg; J J de Soet; J de Lange; F R Rozema
Journal:  Mediators Inflamm       Date:  2014-04-10       Impact factor: 4.711

10.  Prospective evaluation of clinical symptoms of chemotherapy-induced oral mucositis in adult patients with acute leukemia: A preliminary study.

Authors:  Yeon-Hee Lee; Junshik Hong; Inho Kim; Youngnim Choi; Hee-Kyung Park
Journal:  Clin Exp Dent Res       Date:  2019-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.